Abingdon Health Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABDXF research report →
Companywww.abingdonhealth.com
Abingdon Health Plc engages in the development, manufacture, and distribution of diagnostic devices worldwide. The company offers AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test; nucleic acid lateral flow immunoassays; PCRD and PCRD FLEX, nucleic acid lateral flow tests used for rapid readouts post isothermal amplification; Abingdon Simply Test, a range of self-tests; and 2019-nCoV Antigen Test, a rapid lateral flow test for the qualitative detection of antigens to SARS-CoV-2. It also provides AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader.
- CEO
- Christopher William Hand
- IPO
- 2022
- Employees
- 113
- HQ
- York, GB
Price Chart
Valuation
- Market Cap
- $30.32M
- P/E
- -14.01
- P/S
- 2.33
- P/B
- 7.21
- EV/EBITDA
- -6.56
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 34.11%
- Op Margin
- -45.70%
- Net Margin
- -33.88%
- ROE
- -55.91%
- ROIC
- -59.58%
Growth & Income
- Revenue
- $8.43M · 37.39%
- Net Income
- $-3,415,000 · -168.69%
- EPS
- $-0.01 · -121.43%
- Op Income
- $-3,509,000
- FCF YoY
- -107.53%
Performance & Tape
- 52W High
- $0.18
- 52W Low
- $0.12
- 50D MA
- $0.15
- 200D MA
- $0.15
- Beta
- 0.12
- Avg Volume
- 20.00K
Get TickerSpark's AI analysis on ABDXF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ABDXF Coverage
We haven't published any research on ABDXF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ABDXF Report →